Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: A case report

被引：2

作者：

Menichetti M. ^{[1
]}

Rosso S. ^{[1
]}

Menegatti E. ^{[1
]}

Pazzaglia M. ^{[1
]}

机构：

[1] UO PS/MURG OC S. Maria Delle Croci, Viale Randi 5, Ravenna

来源：

Journal of Medical Case Reports | / 9卷 / 1期

关键词：

Anticoagulant; Case report; Elderly; Mortality risk; Pulmonary embolism; Rivaroxaban;

D O I：

10.1186/s13256-015-0758-6

中图分类号：

学科分类号：

摘要：

Introduction: Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The standard treatment for pulmonary embolism is anticoagulant therapy using low molecular weight heparin, fondaparinux and a Vitamin K antagonist, but a recent clinical trial showed that rivaroxaban, an oral factor Xa inhibitor, was as effective as standard therapy for the initial and long-term treatment of pulmonary embolism and had less bleeding complications. Case presentation: The present report describes the case of an 80-year-old white man with an intermediate to low early mortality risk of pulmonary embolism. He was successfully treated with rivaroxaban (administered orally as monotherapy), demonstrating rapid benefit without any adverse events. Conclusion: Rivaroxaban, particularly in the acute phase of pulmonary embolism, may be considered an effective and safe therapeutic choice even in elderly patients, a population less represented in clinical trials. © 2015 Menichetti et al.

引用

共 12 条

[1]

Heit J.A., The epidemiology of venous thromboembolism in the community, Arterioscler Thromb Vasc Biol., 28, pp. 370-372, (2008)

[2]

Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G., Et al., Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality, Thromb Haemost, 98, pp. 756-764, (2007)

[3]

Stein P.D., Henry J.W., Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy, Chest., 108, pp. 978-981, (1995)

[4]

Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J., Risk factors for deep vein thrombosis and pulmonary embolism: A population based case-control study, Arch Intern Med., 160, pp. 809-815, (2000)

[5]

Buller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., Minar E., Et al., Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med., 366, pp. 1287-1297, (2012)

[6]

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism, Eur Heart J, 35, pp. 3145-3146, (2014)

[7]

Aujesky D., Obrosky D.S., Stone R.A., Auble T.E., Perrier A., Cornuz J., Et al., Derivation and validation of a prognostic model for pulmonary embolism, Am J Respir Crit Care Med., 172, pp. 1041-1046, (2005)

[8]

Jimenez D., Aujesky D., Diaz G., Monreal M., Otero R., Marti D., Et al., Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism, Am J Respir Crit Care Med, 181, pp. 983-991, (2010)

[9]

Fraga M., Taffe P., Mean M., Hugli O., Witzig S., Waeber G., Et al., The inter-rater reliability of the Pulmonary Embolism Severity Index, Thromb Haemost., 104, pp. 1258-1262, (2010)

[10]

Goldhaber S.Z., Bounameaux H., Pulmonary embolism and deep vein thrombosis, Lancet., 379, pp. 1835-1846, (2012)

← 1 2 →